MSI Diagnostic Testing Available for Precision Cancer Immunotherapy BIRMINGHAM, Ala.--(BUSINESS WIRE)-- CIRCULOGENE, a leading liquid biopsy company advancing precision medicine through personalized molecular genetics testing, has announced the availability of microsatellite instability (MSI) biomarker testing for [...]
AACR 2016 Research Shows Circulogene Liquid Biopsy Excels at Real-Time Monitoring of Cancer Mutations Interlab comparison demonstrates Circulogene’s blood-drop-volume liquid biopsy assay is fastest, most accurate process to date for tracking and treating cancer BIRMINGHAM, Ala., – [...]
Proprietary Finger-Stick Cancer Monitoring Technology Launches Circulogene Theranostics into Liquid Biopsy Market Breakthrough, cell-free DNA testing method enables fast, accurate, personalized cancer monitoring and treatment guidance with a single blood drop BIRMINGHAM, Ala., November 10, [...]
Rachel Lindley of WBHM's Magic City Marketplace and Cindy Fisher Crawford, Editor, Birmingham Business Journal, discuss the latest news from the week of August 18, 2015. In this week's events, Crawford breaks the latest news [...]
Birmingham Business Journal reported on Birmingham's latest breakthrough biotechnology company, Circulogene Theranostics and their recent surge of local investment. The article includes interviews with Mike Mullen, CEO and President, Dr. Chen Hsiung-Yeh, Chief Scientific Officer, [...]
MOJ Cell Science & Report published an editorial written by Circulogene's Chief Scientific Officer, Dr. Chen-Hsiung Yeh, on Next-Generation Sequencing and Targeted Cancer Therapy. The complex nature of cancer and the transformation of cancer care, [...]
